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Metformin ameliorates core deficits in a Fragile X syndrome mouse model 1 
 2 
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Fragile X syndrome is the leading monogenic cause of ASD. Trinucleotide repeats in the 8 
FMR1 gene abolish FMRP protein expression, leading to hyperactivation of ERK and 9 
mTOR signaling, upstream of mRNA translation. Here we show that metformin, the 10 
most widely used anti-type 2 diabetes drug, rescues core phenotypes in Fmr1-/y mice and 11 
selectively normalizes Erk signaling, Eif4e phosphorylation and the expression of 12 
Mmp9. Thus, metformin is a potential FXS therapeutic.  13 
 Dysregulated mRNA translation is linked to core pathologies diagnosed in the Fragile X 14 
neurodevelopmental Syndrome (FXS), such as social and behavior problems, developmental 15 
delays and learning disabilities1,2. In the brains of FXS patients and knockout mice (Fmr1-/y; 16 
X-linked Fmr1 deletion in male mice), loss of Fragile X mental retardation protein (FMRP) 17 
results in hyperactivation of the mammalian/mechanistic target of rapamycin complex 1 18 
(mTORC1) and the extracellular signal-regulated kinase (ERK) signaling pathways1,2. 19 
Consistent with increased ERK activity, eukaryotic initiation factor 4E (eIF4E) 20 
phosphorylation is elevated in the brain of FXS patients and Fmr1-/y mice, thereby promoting 21 
translation of the mRNA encoding for matrix metalloproteinase 9 (MMP-9), which is elevated 22 
in the brains of both FXS patients and the Fmr1-/y mice1-5. In accordance with these findings, 23 
knockout of Mmp9 rescues the majority of phenotypes in Fmr1-/y mice. MMP-9 degrades 24 
components of the extracellular matrix, including proteins important for synaptic function and 25 
maturation, which are implicated in FXS and autism spectrum disorders (ASD). Recent 26 
observations indicate that metformin, a first-line therapy for type 2 diabetes, imparts 27 
numerous health benefits beyond its original therapeutic use, such as decreased cancer risk 28 
and improved cancer prognosis6. Metformin inhibits the mitochondrial respiratory chain 29 
complex 1, leading to a decrease in cellular energy state and thus activation of the energy 30 
sensor AMP-activated protein kinase (AMPK)6. Several AMPK-independent activities of 31 
metformin have also been reported7,8. Since metformin suppresses translation by inhibiting 32 
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mTORC1 and ERK pathways, we reasoned that metformin could have beneficial therapeutic 33 
effects in Fmr1-/y mice9. 34 
 35 
Adult (8-12 weeks old) wild-type (WT) and Fmr1-/y mice were injected intraperitoneally (i.p.) 36 
with metformin (200 mg/kg/day, a concentration previously used in preclinical studies8) or 37 
vehicle for 10 days (Fig. 1a). Metformin, as previously reported10, crosses the blood brain 38 
barrier (BBB), achieving lower concentrations in brain than plasma after acute and chronic 39 
injection (Supplementary Figs. 1 and 2). Twenty-four hours after the last injection of 40 
metformin, mice were subjected to a social novelty test. Vehicle-treated Fmr1-/y mice were 41 
impaired in the preference for social novelty, showing no preference for interaction with the 42 
novel (stranger 2) over the original social stimulus (stranger 1; Fig. 1b,c). Metformin 43 
treatment restored the impaired preference of Fmr1-/y mice for the novel stranger mouse, thus 44 
rescuing the social deficit. Next, we examined the effect of metformin on repetitive behavior, 45 
a core characteristic of FXS patients that is recapitulated in Fmr1-/y mice as increased self-46 
grooming1,11. Metformin reversed the increased grooming in Fmr1-/y mice (Fig. 1d) and 47 
decreased the number of grooming bouts (Fig. 1e) measured 24 hours after the last injection. 48 
Prolonged exposure to metformin is required to rescue behavioral deficits since one- and five-49 
day treatments of Fmr1-/y mice failed to correct the core FXS phenotypes (Supplementary 50 
Figs. 3 and 4). We tested several other behavioral phenotypes including audiogenic seizures, 51 
hyperactivity and cognitive function in Fmr1-/y mice; we observed no cognitive impairment in 52 
Fmr1-/y mice.  Ten-day treatment with metformin reduced the incidence of seizures but did 53 
not impact hyperactivity (Supplementary Figs. 5 and 6). 54 
 55 
Neurons from FXS patients and Fmr1-/y mice exhibit aberrant spine morphology1,11. We 56 
observed spine dysmorphogenesis in Fmr1-/y mice as evidenced by increased density of 57 
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dendritic spines in CA1 hippocampal pyramidal neurons, along with fewer mature stubby and 58 
mushroom spines, and an increased number of immature filopodia-like spines (Fig. 1f,g,h). 59 
Ten-day metformin administration corrected the dendritic abnormalities in Fmr1-/y mice (Fig. 60 
1f,g,h).  61 
 62 
Fmr1-/y mice also display exaggerated group 1 mGluR-dependent LTD1,12. Ten-day 63 
metformin treatment rescued exaggerated LTD (Fig. 1i,j,k) in Fmr1-/y mice, as well as 64 
restored excitatory synaptic activity to WT levels in hippocampal slices of Fmr1-/y mice 65 
(Supplementary Fig. 7).  66 
 67 
A hallmark of post-adolescent FXS male patients and Fmr1-/y mice is macroorchidism11,12. 68 
Ten-day metformin administration also led to a partial reduction in testicular weight in Fmr1-69 
/y mice (Fig. 2a).  70 
 71 
Fmr1-/y mice exhibit elevated mRNA translation1,12. Consistent with previous studies1,12,13, 72 
basal levels of protein synthesis were elevated in Fmr1-/y mice and ten-day metformin 73 
treatment reduced the excessive translation (Fig. 2b).  74 
 75 
ERK and mTOR signaling pathways are hyperactivated in Fmr1-/y mice1,2,12,13. Ten-day 76 
metformin treatment restored the levels of phosphorylated mitogen-activated protein kinase 77 
(Mapkk encoding Mek; p-MEK), p-ERK, p-eIF4E, and MMP-9 in prefrontal cortex and 78 
hippocampus (Fig. 2c-j), whereas the levels of p-S6 remained elevated in the hippocampus of 79 
metformin-treated Fmr1-/y mice (Supplementary Figs. 8a,b and 9). Similarly, ten-day 80 
metformin treatment rescued increased p-ERK in the striatum, but not in the cerebellum 81 
(Supplementary Fig. 10a,b) of Fmr1-/y mice, and affected specific known synaptic FMRP 82 
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targets, MAP2 and synapsin, with no effect on eEF2 and PUM2 levels14 (Supplementary 83 
Fig. 11). Apart from the brain, p-ERK was increased in the liver, but not in gonads 84 
(Supplementary Fig. 10c,d) of Fmr1-/y mice. Ten-day metformin treatment did not rescue the 85 
increased ERK phosphorylation in the liver (Supplementary Fig. 10d), suggesting the 86 
implication of other pathways12 or endocrine regulation outside the brain of Fmr1-/y mice.  87 
 88 
Ten-day metformin administration did not activate Ampk in the prefrontal cortex and 89 
hippocampus of Fmr1-/y mice, as evidenced by the lack of increased phosphorylated Ampk (p-90 
AMPK), and of its downstream substrates p-Acc1, p-Tsc2, p-Raptor, and p-Braf (Ser729) in 91 
metformin-treated mice (Supplementary Figs. 8c-k and 9a). These findings are consistent 92 
with previous reports showing that chronic metformin administration does not increase p-93 
AMPK in the brain15,16. It is not immediately clear why ten-day metformin administration 94 
does not increase p-AMPK in the brain, however, in accordance with previous studies17,18, a 95 
single injection of 200 mg/kg, i.p. metformin induced a transient increase in p-AMPK 96 
(Supplementary Fig. 1c). A plausible explanation for the change in ERK signaling following 97 
chronic metformin treatment is due to the rescue of elevated expression of Braf and Craf in 98 
Fmr1-/y mice (Supplementary Fig. 9)19. 99 
 100 
Presently, there is no cure for FXS or ASD, and recently completed clinical trials in teenagers 101 
or adults with FXS are not promising20. Our data show that metformin, the most widely used 102 
anti-diabetic FDA-approved drug for patients aged 10 years and older, corrects most 103 
phenotypic deficits in the adult FXS mouse model. Thus, metformin, whose long-term safety 104 
and tolerability are extensively documented in clinical practice, is one of the very few 105 
compounds that can be promptly repurposed as an FXS therapeutic for patients aged 10 years 106 
and older. Moreover, our data are in accordance with a recent finding that metformin 107 
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treatment corrects circadian and cognitive deficits in a Drosophila Fragile X model21. 108 
Importantly, we present a potential molecular mechanism for metformin in FXS by showing 109 
that chronic metformin treatment corrects enhanced Raf/Mek/Erk signaling and Mmp9 110 
expression in Fmr1-/y mice (Fig. 2 and Supplementary Fig. 9). Similarly, lovastatin, a drug 111 
that downregulates ERK signaling, also rescued audiogenic seizures, exaggerated mGluR-112 
LTD, and decreased general protein synthesis in Fmr1-/y mice13. Metformin, however, corrects 113 
a broader range of phenotypes than lovastatin. Combining these findings bolster the critical 114 
role of aberrant ERK activity in engendering FXS-like phenotypes in FXS. Since Mmp9 115 
mRNA translation is stimulated by eIF4E phosphorylation and knockout of Mmp9 reversed 116 
abnormal phenotypes in Fmr1-/y mice1,5, it is highly likely that the rescue by metformin is 117 
selectively mediated via ERK/eIF4E-dependent normalization of MMP-9 expression in the 118 
brain, providing a very strong mechanistic avenue for the action of metformin. We cannot 119 
exclude a yet unidentified, peripherally-mediated rescue mechanism, given the known 120 
inhibition of gluconeogenesis by metformin or altering the gut microbiota22. Such peripheral 121 
phenotypes are linked to autism, intellectual disability and FXS, and have been shown to 122 
affect brain plasticity23. 123 
 124 
  125 
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METHODS  126 
Methods and any associated references are available in the online version of the paper. 127 
 128 
SUPPLEMENTARY INFORMATION 129 
Supplementary Information is available in the online version of the paper. 130 
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FIGURE LEGENDS 177 
 178 
Figure 1 Chronic metformin treatment corrects social deficit, repetitive behavior, aberrant 179 
dendritic spine morphology and exaggerated LTD in Fmr1-/y mice. (a) Metformin or vehicle 180 
was injected i.p. over 10 days (200 mg/kg/day) followed by analysis of social behavior, 181 
grooming, dendritic spine morphology, and LTD. Preference for social novelty was assessed 182 
in the three-chamber social interaction test by measuring time spent with the novel social 183 
stimulus (stranger 2 (S2)) or the previously encountered mouse (S1) (b); and time spent in 184 
each chamber (c). Vehicle-treated WT (n = 10) and Fmr1-/y (n = 10), and metformin-treated 185 
WT (n = 9) and Fmr1-/y (n = 12). (d) Self-grooming test with total time spent grooming and 186 
(e) total number of grooming bouts. Vehicle-treated WT (n = 10) and Fmr1-/y (n = 10), and 187 
metformin-treated WT (n = 8) and Fmr1-/y (n = 12). (f) Golgi-cox staining of CA1 dendritic 188 
spines in metformin or vehicle-injected WT and Fmr1-/y mice. Scale bar: 2 μm. (g) 189 
Quantification of spine density, measured as the number of spines per 10 μm and (h) spine 190 
subtype analysis (S/M = spiny/mushroom; F = filopodial) presented as a fraction of total 191 
spines for each subtype (n = 4 in each group). mGluR-LTD was measured in CA1 in response 192 
to DHPG (50 μm for 10 min) in slices prepared from (i) vehicle-treated WT (n = 9) and Fmr1-193 
/y (n = 17) mice, and (j) metformin-treated WT (n = 9) and Fmr1-/y (n = 15) mice. (k) fEPSP 194 
slope during the last 10 minutes of recording. All values are shown as mean ± s.e.m. ***P < 195 
0.001, **P < 0.01, *P < 0.05 versus all other groups; N.S., not significant; calculated by two-196 
way ANOVA with Tukey’s post hoc test. 197 
 198 
Figure 2 Chronic metformin treatment corrects macroorchidism, increased translation and 199 
reduces the phosphorylation of upstream eIF4E effectors. (a) Mean testicular weight of 200 
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vehicle- and metformin-treated WT and Fmr1-/y mice. Vehicle-treated WT (n = 6) and Fmr1-/y 201 
(n = 6), and metformin-treated WT (n = 6) and Fmr1-/y (n = 7). (b) Western blots of lysates 202 
from hippocampal slices incubated with puromycin to measure basal rates of protein 203 
synthesis. β-tubulin was used as a loading control. Puromycin incorporation is presented as 204 
percentage change relative to vehicle-treated WT slices (n = 7 in each group). Representative 205 
western blots of lysates from vehicle- and metformin-treated WT and Fmr1-/y mice and 206 
quantification of phosphorylation and total levels of (c) MEK, (d) ERK, (e) eIF4E and (f) 207 
MMP-9 in prefrontal cortex and (g) MEK, (h) ERK, (i) eIF4E and (j) MMP-9 in 208 
hippocampus. GAPDH was used as a loading control. For quantification, the phospho-protein 209 
signal was normalized first against total protein, and then presented relative to vehicle-treated 210 
WT (n = 6 in each group, n = 5 for MMP-9 in prefrontal cortex). All values (a-h) are shown 211 
as mean ± s.e.m. ***P < 0.001, **P < 0.01, *P < 0.05 versus all other groups; N.S., not 212 
significant; calculated by two-way ANOVA with Tukey’s post hoc test. 213 
 214 
 215 
  216 
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ONLINE METHODS 217 
Knockout mice and metformin administration. Fmr1-/y (the Fmr1 gene is on the X mouse 218 
chromosome, thus male animals have a -/y genotype; y corresponds to Y mouse 219 
chromosome), and WT mice on C57BL/6J background (Jackson Laboratories) were 220 
previously described21. Food and water were provided ad libitum and mice were kept on a 12-221 
h light/dark cycle (7:00-19:00 light period). After weaning at postnatal day 21, mice were 222 
group housed (maximum of five per cage) by sex. Cages were maintained in ventilated racks 223 
in temperature (20-21°C) and humidity (~55%) controlled rooms. Standard corncob bedding 224 
was used for housing (Harlan Laboratories Inc.).  225 
All animals received a 10-day chronic treatment with metformin (200 mg/kg/day, 226 
intraperitoneal injection) or vehicle (saline), except when indicated otherwise. Injecting 227 
groups were randomized over all cages. 228 
All procedures were in compliance with the Canadian Council on Animal Care guidelines and 229 
were approved by McGill University and Université de Montréal.  230 
 231 
Three-chamber sociability and preference for social novelty tests. The apparatus consisted 232 
of three Plexiglas chambers: the central chamber (36 cm x 28 cm x 30 cm) was divided from 233 
two side chambers (each chamber: 29 cm x 28 cm x 30 cm) by Plexiglas walls, as previously 234 
described (Stoelting Co.)24,25. Each side was accessible to the mouse from the center through a 235 
doorway covered by a removable sliding door. A camera was mounted above the apparatus to 236 
record testing. The test consisted of 3 phases: habituation, sociability, and preference for 237 
social novelty. In the first part, three-month old male mice were placed in the middle chamber 238 
and were allowed to explore all three empty chambers for 10 min. After this period of 239 
habituation, mice were gently guided back to the center chamber of the apparatus and the 240 
sliding doors to access the remaining two chambers were closed. In the second part of the test, 241 
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an unfamiliar mouse (stranger 1) was placed into one of the two remaining side chambers, 242 
enclosed in a wire cage to ensure that only the test mouse could initiate social interaction. An 243 
empty wire cage, identical to the wire cage housing stranger 1, was placed in the 244 
corresponding spot on the other side chamber. The side doors were then opened 245 
simultaneously to allow the test mouse to explore the three-chamber apparatus for 10 min to 246 
assess sociability. At the end of the 10 min period the test mouse was gently guided to the 247 
central chamber and sliding doors were closed. In the final part of the test, a new unfamiliar 248 
mouse (stranger 2) was placed in the previously empty wire cage, and the test mouse could 249 
explore the three chambers for an additional 10 min to assess preference for social novelty. 250 
Stranger mice consisted of age- and sex-matched C57BL/6J mice that were group-housed (4 251 
per cage) and were used in a counterbalanced way. The empty wire cages were alternated 252 
between side chambers for different test mice. Stranger 1 and stranger 2 mice always came 253 
from different home cages. Mice were tested in the morning during the light cycle. Time spent 254 
directly sniffing, defined as the time the test mouse spent in direct nose contact with wire 255 
cages, time spent in each chamber, and the number of transitions into the chambers, were 256 
scored manually. Data was scored in a blind to genotype manner, and if possible by a third 257 
party, using a stopwatch. Statistical analysis included mixed ANOVA with a Tukey’s post 258 
hoc test for multiple comparisons. 259 
 260 
Self-grooming test. The setup consisted of a new Plexiglas cage equal in size to the home 261 
cage, containing approximately 1 cm of bedding material but no nesting material. A camera 262 
was placed vertically in front of the cage for recording. Fmr1-/y and WT mice (3 month old 263 
males) were placed in a new Plexiglas cage and allowed to explore for 20 minutes. The first 264 
10 minutes of the experiment were considered as the habituation phase, followed by the final 265 
10 minutes which were used to acquire self-grooming data. Total time spent grooming and the 266 
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total number of grooming bouts was used to analyze grooming behavior. Data was manually 267 
scored in a blind to genotype manner, and if possible by a third party, using a stopwatch. All 268 
measures were analyzed with a two-way ANOVA with Tuckey’s post hoc test. 269 
 270 
Audiogenic seizures. Mice (male, P21-P24) were chronically injected for 10 days with 271 
metformin (200 mg/kg) or vehicle prior to experimentation. Mice were individually 272 
habituated in an isolated, sound insulated behavioral chamber made of transparent plastic (28 273 
x 17 x 16 cm outside dimensions) for 2 min and were subjected to a 130 dB acoustic stimulus 274 
using a personal alarm (Vigilant) for 2 min, where the incidence of wild running, tonic-clonic 275 
seizures, and status epilepticus were recorded.  276 
 277 
Open-field exploration. Animals (male, 8-12 weeks old) were first habituated to the dimly lit 278 
experimental room (∼15 lux) for 30 min and then individually placed in an illuminated clear 279 
Plexiglas chamber (40 x 40 x 40 cm, ∼1200 lux) with a white floor. Animals were allowed to 280 
explore freely for 10 min following an initial 1 min habituation phase. Total path length, as a 281 
measure of hyperactive behavior, was calculated using ANY-maze. 282 
 283 
Light-dark transition test. The test apparatus was composed of two adjacent chambers 284 
connected by a small opening: a dark enclosed chamber made of black Plexiglas (20 x 40 x 40 285 
cm) and a chamber with three clear Plexiglas walls with an open top. Mice (male, 8-12 weeks 286 
old) were placed into the “light” side (∼390 lux) and allowed to explore freely for 10 min. An 287 
entry was defined as the mouse placing all 4 feet into each zone. 288 
 289 
Morris water maze and reversal learning. Chronic metformin (200 mg/kg) or vehicle 290 
(saline) administration started 5 days prior to training and lasted throughout the whole course 291 
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of testing, for a total of 10 days. The circular water maze pool was 100 cm in diameter. The 292 
water was maintained at 22-23°C and made opaque by addition of white tempera. The 293 
platform was 10 cm in diameter. Mice (male, 8-12 weeks old) were handled daily for 3 days 294 
before the start of the experiment. During the experiment, mice were trained three times per 295 
day with an inter-trial interval of 30 min over five consecutive days (Day 1-5). Each trial was 296 
a maximum of 120 s, or until the mouse found the platform. If the mouse did not find the 297 
platform in the assigned time, it was guided to the platform and stayed there for 10 s before 298 
being returned to the home cage. For the probe test (Day 6), the platform was removed and 299 
each mouse was allowed to swim for 30 s. For the reversal learning paradigm, in which the 300 
hidden platform was relocated to the opposite quadrant (Day 6-7), mice received the same 301 
training procedure as described before. The platform was removed for the probe test of the 302 
reversal learning (Day 8) to assess spatial retention. The experiment was recorded with a 303 
video tracking system (HVS Image) whereby latency to reach the platform during acquisition 304 
and time spent in target quadrant during the probe trials was determined. 305 
 306 
Contextual fear conditioning. During acquisition (5 min), two foot shocks of 0.7 mA for 1 s 307 
separated by 60 s were administered after an initial 2-min period of context exploration. 308 
Twenty-four hours after training, mice (male, 8-12 weeks old) were tested for contextual fear 309 
memory in the same context for 5 min, as assessed by the percentage of total time spent 310 
freezing in the conditioning context. Behavioral scoring was carried out for a 5-min period, in 311 
5-s intervals, assigning animals as either ‘freezing’ or ‘not freezing’. Freezing (%) indicates 312 
the number of intervals where freezing was observed, divided by the total number of 5 s 313 
intervals. 314 
 315 
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Novel object recognition. On day one, mice (male, 8-12 weeks old) were first habituated for 316 
15 min in a square testing arena (40 x 40 cm) followed by 15 min in an opaque box before 317 
being returned to their home cages. On day two and three, mice were put back in the arena for 318 
15 min and presented with two identical objects (familiar) within specific areas (counter-319 
balanced locations of objects). Mice were allowed to freely explore the arena and objects, 320 
followed by 15 min in an opaque box and then returned to their home cages. On day four, one 321 
of the objects (used for days two and three) was replaced with a third object (novel object) 322 
and the mice were allowed to explore the environment for 15 min. Time spent exploring each 323 
object was recorded. Object exploration was defined as the time spent interacting with an 324 
object, when the mouse was sniffing and touching the object. Total exploration time was 325 
quantified as the time interacting with both objects. To assess preferential attention to an 326 
object, a discrimination index was calculated (tnovel – tfamiliar)/(tnovel + tfamiliar). A positive index 327 
represents a preference for the novel object. 328 
 329 
Western blot and antibodies. The brain tissue (3 month old males) was homogenized in 330 
RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium 331 
deoxycholate, 5 mM EDTA pH 8.0, 1 mM EGTA pH 8.0, 10 mM NaF, 1 mM β-332 
glycerophosphate, 1 mM sodium orthovanadate) containing protease inhibitors (Roche). 333 
Protein extracts were heat denatured and resolved by SDS-PAGE or gradient precast 334 
(Thermofisher Scientific). Following electrophoresis, proteins were transferred to 335 
nitrocellulose membranes and western blotting was performed. Membranes were stripped in 336 
25 mM glycine-HCl pH 2.0, 1% SDS for 30 min at room temperature, followed by washing in 337 
TBS-T before re-probing. Immunoreactivity was detected by enhanced chemiluminescence 338 
(plus-ECL; Perkin Elmer Inc.) after exposure to an X-Ray film (Denville Scientific Inc.). 339 
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Quantification of immunoblots was performed using ImageQuant 5.2. Values were 340 
normalized against GAPDH. 341 
The following antibodies were used: eIF4E (610270, BD Transduction Laboratories); 342 
phospho-eIF4E (NB-100-79938, Novus Biologicals); ERK (sc-93, Santa Cruz); phospho-343 
ERK (4370, Cell Signaling); MEK1/2 (4694, Cell Signaling); phospho-MEK1/2 (9154, Cell 344 
Signaling); FMRP (4317, Cell Signaling); MMP-9 (TP221, Torrey Pines); AMPK (2532, Cell 345 
Signaling); phospho-AMPK (2535, Cell Signaling); ACC1 (4190, Cell Signaling); phospho-346 
ACC1 (11818, Cell Signaling); S6 (2217, Cell Signaling); phospho-S6 (2215, Cell Signaling); 347 
TSC2 (4308, Cell Signaling); phospho-TSC2 (1387, Cell Signaling); Raptor (2280, Cell 348 
Signaling); phospho-Raptor (2083, Cell Signaling); c-Raf (53745, Cell Signaling); b-Raf 349 
(ab33899, Abcam); phospho-b-Raf S729 (ab124794, Abcam); phospho-b-Raf S602 (PA5-350 
38412, Thermo Fisher Scientific); Synapsin (5297, Cell Signaling); eEF2 (2332, Cell 351 
Signaling); MAP2 (ab5392, Abcam); PUM2 (A300-202A, Bethyl Laboratories); GAPDH (sc-352 
32233, Santa Cruz); β-actin (A5441, Sigma); secondary anti-mouse and anti-rabbit (GE 353 
Healthcare). GAPDH (sc-32233, Santa Cruz); secondary anti-mouse and anti-rabbit (GE 354 
Healthcare). For statistical analysis of western blots results we used two-way ANOVA with 355 
Tukey’s post hoc test, and one-way ANOVA with Tukey’s post hoc test (p-AMPK in the 356 
hippocampus, single injection metformin experiment).  357 
 358 
LTD recordings. For analysis of hippocampal LTD, male 31- to 34-day-old wildtype or 359 
Fmr1-/y, treated with either saline or metformin (as described above) were used. After 360 
obtaining hippocampal slices (400 μm thickness), CA1 and CA3 hippocampal regions were 361 
isolated by a surgical excision and incubated for 2 h at 32°C in oxygenated artificial cerebral 362 
spinal fluid for recovery (ACSF; 124 mM NaCl, 5 mM KCl, 1.25 mM NaH2PO4, 2 mM 363 
MgSO4, 2 mM CaCl2, 26 mM NaHCO3, and 10 mM glucose). Later, slices were placed in a 364 
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recording chamber at 27–28°C and perfused with ACSF for an additional 30 min. A glass 365 
electrodes (2–3 MΩ) was filled with ACSF and gently placed on CA1 stratum radiatum to 366 
record field EPSPs (fEPSPs), evoked by stimulation of Schaffer collaterals. The stimulating 367 
concentric bipolar tungsten electrode was placed in the mid-stratum radiatum proximal to the 368 
CA3 region to deliver 0.1 ms pulses at 0.033 Hz. The intensity was adjusted to evoke fEPSPs 369 
with 60% maximal amplitude. mGluR-LTD was induced by perfusing a group I mGluR 370 
agonist (S)-3,5-dihydroxyphenylglycine (DHPG; 50 μM; Tocris Bioscience) for 10 min in 371 
ACSF. fEPSPs were recorded for a total of 60 min after induction onset. Slope measurements 372 
were performed on digitized analog recordings using the Clampfit analyze function, between 373 
10% and 90% of maximal fEPSP amplitude during an epoch defined by constant cursor 374 
placements. This setting excluded fibre volley and population spikes. Data was then analyzed 375 
using two-way ANOVA with Tukey’s post hoc test. 376 
 377 
Miniature EPSC recordings. Organotypic hippocampal slices were prepared from WT and 378 
Fmr1-/y mice (postnatal day 4-6). The brain was removed and dissected in Hanks' balanced 379 
salt solution (Invitrogen)-based medium. Corticohippocampal slices (400 μm thick) were 380 
obtained with a McIlwain tissue chopper (Campden Instruments). Slices were placed on 381 
Millicell culture plate inserts (Millipore) and incubated in OptiMem (Invitrogen)-based 382 
medium in a humidified atmosphere of 5% CO2 and 95% O2 at 37°C.  383 
Experiments were performed after 14-20 days in culture. Cultures were treated with 384 
metformin (50 μM) or vehicle (Optimem media) for 4-5 days before electrophysiology 385 
experiments which were performed blinded to treatment. Whole-cell recordings were obtained 386 
from CA1 pyramidal neurons using borosilicate pipettes (3–6 MΩ) filled with intracellular 387 
solution containing (in mM) 132 CsMeSO3, 8 CsCl, 0.6 EGTA, 10 diNa-phosphocreatine, 10 388 
HEPES, 4 ATP-Mg2+, 0.4 GTP-Na (pH 7.25-7.30 with CsOH, 275-280 mOsmol). 389 
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Spontaneous miniature EPSCs (mEPSCs) were recorded in the presence of TTX (5 nM; 390 
Abcam) in ACSF containing (in mM) 124 NaCl, 2.5 KCl, 1 NaH2PO4, 26 NaHCO3, 2 CaCl2, 391 
2 MgSO4, 10 D-Glucose, (pH 7.37-7.41 with NaCl, 295-305 mOsm). Recordings were 392 
obtained using a Multiclamp 700 A amplifier and a 1440 A Digidata acquisition board 393 
(Molecular Devices). Signals were low-pass-filtered at 2 kHz, digitized at 20 kHz and stored 394 
on a PC. mEPSCs were recorded in whole cell voltage-clamp at a holding potential of -70 mV 395 
and identification of mEPSCs was confirmed by application of CNQX (10 µM). Access 396 
resistance was routinely monitored and recordings were only included if <30 MΩ and with 397 
variation <25% over the recording period. For analysis, mEPSC traces were filtered at 2.8 398 
kHz (Bessel filter) using pClamp10 software (Molecular Devices) and miniature events were 399 
analyzed using MiniAnalysis (Synaptosoft). Two-way ANOVA with Tukey’s post hoc test 400 
was used to assess statistical significance. 401 
 402 
Analysis of neuronal morphology by Golgi-Cox Staining. Four male mice per genotype 403 
and treatment (3 months old) were used for morphological analysis. Rapid GolgiKit (FD 404 
NeuroTechnologies) was used for the staining procedure according to the manufacturer’s 405 
instructions. Briefly, whole brains were isolated from each animal, rinsed once in Milli-Q 406 
water and quickly immersed into impregnation solution (A+B), stored at room temperature in 407 
the dark for three weeks. 120 µm sections were cut, processed, and mounted following the 408 
protocol provided with the kit. Hippocampal sections were imaged on a confocal microscope 409 
(LSM710, Zeiss). Apical dendrites of five pyramidal neurons from the hippocampal CA1 area 410 
per animal were analyzed. To measure spine density on apical shaft dendrites, the number of 411 
spines on each successive 25 mm segment was counted starting at the soma and continuing to 412 
the end of the dendrite. Densities for each segment and for each neuron were pooled to get an 413 
average spine density per animal; the difference between genotypes was analyzed by two-way 414 
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ANOVA with Tukey’s post hoc test. For each neuron, the spine morphology was determined 415 
by the first 10 spines in every 25 µm bin along the apical shaft. Spines were assigned one of 416 
the five morphological categories based on published methods24-26; A:Thin, B:Stubby, 417 
C:Mushroom, D:Filopodia, E:Branched. Chi-Square analysis was used to compare the 418 
distribution of spines in these categories between genotypes. For statistical analysis, we used 419 
two-way ANOVA with Tukey’s post hoc test. 420 
 421 
Measurement of de novo protein synthesis. To assess whether metformin corrects increased 422 
translation in Fmr1-/y mice, we measured de novo protein synthesis in hippocampal slices 423 
using the SUnSET puromycin incorporation assay24,27. Transverse hippocampal slices (400 424 
µm) were prepared from 5-6 week old mice and allowed to recover for at least 3 h. Puromycin 425 
labeling was performed as described24,27,28. Briefly, the slices were incubated with puromycin 426 
(Sigma, 5 µg/ml in ACSF) for 45 min and then processed for western blotting, as described 427 
before, using an anti-puromycin antibody. Slices processed in parallel but not incubated with 428 
puromycin served as an unlabeled control. Protein synthesis was determined by measuring 429 
total lane signal from 15-250 kDa and subtracting unlabeled protein control. Signals were 430 
quantified using ImageJ, normalized to β-tubulin and presented as percentage change relative 431 
to control. For statistical analysis of western blots results, we used two-way ANOVA with 432 
Tukey’s post hoc test. 433 
 434 
Metformin Bioanalysis, LC-MS/MS. WT mice on C57BL/6J background (Charles River 435 
Laboratories, 8-10 weeks old males) were used for the study. Food and water were provided 436 
ad libitum and mice were kept on a 12-h light/dark cycle (7:00-19:00 light period). For 437 
pharmacokinetic study, the mice received a single dose of metformin (200 mg/kg, i.p.) and the 438 
plasma and brain tissues were collected at 0, 0.5, 1, 2, and 4 h after drug administration. For 439 
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the dose-response study, the mice were treated for 10 days with 25, 50, 100, or 200 mg/kg/day 440 
(i.p.), and the plasma and brain tissues were collected 24 h after the last injection. Brain tissue 441 
homogenate and plasma concentration of metformin was determined by protein precipitation 442 
and liquid chromatography with mass spectrometric detection (LC-MS/MS). Metformin 443 
powder (Sigma), was used to prepare a 1.00 mg/mL solution in DMSO adjusting for salt 444 
factor as applicable. Calibration spiking solutions were prepared at 10.0 20.0, 50.0, 100, 200, 445 
500, 1000, 2000, 5000, 10000, 20000, 50000, and 100000, ng/mL in DMSO from the primary 446 
stock solution. Plasma and brain tissue samples were quickly collected and stored at -70°C. 447 
Brain samples, and blank tissues were homogenized with 3 parts distilled water per g of tissue 448 
for a final processing dilution factor of 4-fold. The resultant blank tissues were utilized for 449 
matrix calibration standards, which were prepared the same day of analysis, on ice at 0.5, 1.0, 450 
2.5, 5.0, 10.0, 25.0, 50.0, 100, 250, 500, 1000, 2500, and 5000 ng/mL; by spiking blank brain 451 
tissue homogenate and plasma matrices at 1:20 with appropriate metformin spiking solution. 452 
Subsequently, an aliquot of the matrix samples, matrix calibration standards, and matrix 453 
blanks were taken and protein precipitated by the addition Labetalol in 100% Acetonitrile 454 
(1:4). The resultant matrix samples, matrix calibration standards, and matrix blanks were 455 
vortexed for 1 min and centrifuged for 10 min at 3300 rpm at 4°C. Then 100 µL of the 456 
resultant supernatant was transferred into a clean 96-well plate and diluted with aqueous 457 
solution (1:1). All matrices; plasma and brain tissue, were processed independently and in 458 
discrete batches containing appropriate matrix study samples, matrix calibration standards, 459 
and matrix blanks respectively. The analysis for each discrete batch was performed on a 460 
LC-MS/MS system: AB Sciex QTRAP 6500, with a Shimadzu Nexera UPLC system utilizing 461 
a ZIC-HILIC 2.1 x 50 mm analytical column, 3.5 µm pore size. An injection volume of 1.5 462 
µL was utilized for all samples and standards, with a flow rate of 1.0 mL/min. The Mobile 463 
Phases consisted of the following: Mobile Phase A – 10 mM Ammonium Acetate in Water, 464 
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Mobile Phase B – 0.1% Formic Acid (v/v) in Acetonitrile. Mass Spectrometry data was 465 
generated with positive Electrospray Ionization (ESI+) using multiple reaction monitoring 466 
(MRM) of the following transitions: Metformin 130.324/60.100 Da and Labetalol (IS) 467 
329.200/311.200 Da. Subsequent least squares linear regression was performed on matrix 468 
calibration standards and the matrix sample concentrations were interpolated from the 469 
appropriate matrix curve. All dilution factors were accounted for in final sample data with 470 
concentration of metformin expressed in ng/mL and ng/g for plasma and brain tissue samples, 471 
respectively.  472 
 473 
Statistical analysis. Experimenters were blinded to the genotype and treatment during testing 474 
and scoring. To decide the sample size in our behavioral, electrophysiological, imaging, and 475 
biochemical experiments, we followed the standard sample sizes used in similar experiments 476 
in each of the relevant fields in the literature. The sample sizes in our behavioral studies were 477 
based on Figure 5b in Mogil et al.26. All experimental n numbers are individual animals unless 478 
otherwise stated – technical replicates of some western blots were carried out. All data are 479 
presented as mean ± s.e.m. Statistical significance was set at 0.05. Statistical results, along 480 
with tests used (one-way ANOVA, two-way ANOVA, and mixed ANOVA), are summarized 481 
in Supplementary Table 1. SPSS (IBM), Statistica (Statsoft), Sigmaplot (Systat Software 482 
Inc.) and Graphpad Prism (Graphpad Software) were used for statistical analysis. 483 
Supplementary Table 1 outlines the statistics used for each figure. 484 
 485 
Data-availability statements. The data supporting the findings of this study are available 486 
from the corresponding author upon request.   487 
 488 
24          Gkogkas, C.G. et al. Cell Rep 9, 1742-1755 (2014). 489 
25 Gkogkas, C.G. et al. Nature 493, 371-377 (2013). 490 
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Supplementary Figure 1 Pharmacokinetic study and AMPK activation in vivo after acute 
metformin (200 mg/kg) treatment. The concentrations of metformin were measured by LC-
MS/MS in the plasma (a), and brain (b) at different time points (0, 0.5, 1, 2, and 4 h) after a 
single metformin injection (200 mg/kg, i.p.) (n = 4 in each group). (c) Representative 
immunoblots of hippocampal lysates from vehicle- and metformin-treated WT and Fmr1-/y 
mice probed for total and phosphorylated AMPK (n = 3 in each group). β-actin was used as 
loading control. For quantification, the phospho-protein signal was normalized first against total 
protein, and then presented relative to vehicle-treated WT. Values are shown as mean ± s.e.m. 
*P < 0.05, versus all other groups; calculated by one-way ANOVA with Tukey’s post hoc test. 
 Supplementary Figure 2 Metformin concentrations in vivo in plasma and brain after a 10-day 
chronic metformin treatment. The concentrations of metformin were measured by LC-MS/MS 
in the plasma (a), and brain (b) 24 h after last metformin injection (25, 50, 100, and 200 mg/kg, 
i.p.) (n = 4 in each group). 
 
 
 
 
 
 
 
 
 
 
 
  
  
Supplementary Figure 3 Five-day metformin treatment (200 mg/kg/day, i.p.) does not rescue 
impaired social and grooming behavior, general translation, and phosphorylated eIF4E in Fmr1-
/y mice. (a) Preference for social novelty was assessed in the three-chamber social interaction 
test by measuring time spent with the novel social stimulus (stranger 2 (S2)) or the previously 
encountered mouse (S1) and time spent in each chamber; calculated by two-way mixed 
ANOVA with Tukey’s post hoc test (n = 8 mice for each group). (b) Self-grooming test with 
total time spent grooming; calculated by two-way ANOVA with Tukey’s post hoc test. Vehicle-
treated WT (n = 6) and Fmr1-/y (n = 6) mice, and metformin-treated WT (n = 7) and Fmr1-/y (n 
= 7) mice. (c) Time-plots of mGluR-LTD measured in CA1 in response to DHPG (50 μM for 
10 min) in slices prepared from vehicle-treated WT (n = 13) and Fmr1-/y (n = 12) mice, and 
metformin-treated WT (n = 12) and Fmr1-/y (n = 12) mice. Quantification (right) of mGluR-
LTD during the last 10 min of recording. Exaggerated mGluR-LTD in metformin-treated Fmr1-
/y mice was rescued. (d) Western blots of lysates from hippocampal slices incubated with 
puromycin to measure basal rates of protein synthesis and β-tubulin as a loading control. 
Puromycin incorporation is presented as percentage change relative to vehicle-treated WT 
slices (n = 3 in each group). (e) Representative immunoblots and blot quantification of total and 
phosphorylated eIF4E in prefrontal cortex and hippocampus from vehicle- and metformin-
treated WT and Fmr1-/y mice (n = 6 in each group). GAPDH was used as a loading control. For 
quantification, the phospho-protein signal was normalized first against total protein, and then 
presented relative to vehicle-treated WT. All values are shown as mean ± s.e.m. ***P < 0.001, 
**P < 0.01, *P < 0.05, N.S. not significant, versus all other groups; calculated by two-way 
repeated measures ANOVA with Tukey’s post hoc test. 
 
 
 
  
 Supplementary Figure 4 One-day metformin treatment (200 mg/kg/day, i.p.) did not rescue 
increased grooming, exaggerated LTD, and increased general translation in Fmr1-/y mice. (a) 
Self-grooming test with total time spent grooming; calculated by two-way ANOVA with 
Tukey’s post hoc test. n = 6 mice for each group. (b) Time-plots of mGluR-LTD measured in 
CA1 in response to DHPG (50 μM for 10 min) in slices prepared from vehicle-treated WT (n = 
11) and Fmr1-/y (n = 10) mice, and metformin-treated WT (n = 12) and Fmr1-/y (n = 8) mice. 
Quantification (right) of mGluR-LTD slope during the last 10 min of recording. (c) Western 
blots of lysates from hippocampal slices incubated with puromycin to measure basal rates of 
protein synthesis and β-tubulin as a loading control. Puromycin incorporation is presented as 
percentage change relative to vehicle-treated WT slices (n = 3 in each group). All values are 
shown as mean ± s.e.m. **P < 0.01, *P < 0.05, N.S. not significant, versus all other groups; 
calculated by two-way repeated measures ANOVA with Tukey’s post hoc test. 
 
 
 
 Supplementary Figure 5 Effect of chronic metformin treatment (200 mg/kg/day, 10 days, i.p.) 
in Fmr1-/y and WT mice on audiogenic seizures and hyperactivity. Audiogenic seizures (a) were 
tested on Fmr1-/y and WT mice in a C57BL6/J (a, left panel) (vehicle-treated WT (n = 2) and 
Fmr1-/y (n = 5) mice, and metformin-treated WT (n = 6) and Fmr1-/y (n = 6) mice) and FVB 
background (a, right panel) (vehicle-treated WT (n = 7) and Fmr1-/y (n = 8) mice, and 
metformin-treated WT (n = 7) and Fmr1-/y (n = 10) mice), and were scored for wild running, 
tonic-clonic seizures and status epilepticus. Vehicle- and metformin-treated WT animals did 
not show any seizures. Metformin-treated Fmr1-/y mice showed reduced occurrence of 
audiogenic seizures. Vehicle-treated Fmr1-/y mice displayed increased activity in the open field 
test (b) for the path length (b, left panel) and velocity (b, right panel) (vehicle-treated WT (n 
= 8) and Fmr1-/y (n = 7) mice, and metformin-treated WT (n = 8) and Fmr1-/y (n = 8) mice), as 
well as an increased number of transitions in the light-dark box (c) compared to vehicle-treated 
WT mice (n = 8 in each group). Ten days metformin treatment did not rescue hyperactivity in 
Fmr1-/y mice. Values are shown as mean ± s.e.m. **P < 0.01, *P < 0.05, N.S. not significant, 
versus all other groups; calculated by two-way repeated measures ANOVA with Tukey’s post 
hoc test. 
 
 
 
 
 
 Supplementary Figure 6 Three behavioral tasks to study cognition in 10-day metformin-
treated (200 mg/kg, i.p.) Fmr1-/y and WT mice (C57BL6/J). Vehicle-treated Fmr1-/y mice did 
not show a significant cognitive impairment compared to vehicle-treated WT mice in spatial 
learning during the 5-day acquisition (a), probe trial (b), acquisition during the 2-day reversal 
learning (3 trials per day) (c), and probe trial of reversal learning (d) in the Morris water maze 
(MWM) (n = 8 in each group). In the contextual fear conditioning (CFC) task (e), no significant 
difference in % of freezing behavior was observed between metformin- and vehicle-treated 
Fmr1-/y and WT mice. Vehicle-treated WT (n = 8) and Fmr1-/y (n = 8) mice, and metformin-
treated WT (n = 8) and Fmr1-/y (n = 10) mice. In the novel object recognition (NOR) task (f), 
no difference in % of preference for novelty was observed between all the tested groups (n = 8 
in each group). 
 Supplementary Figure 7 Metformin restores excitatory synaptic activity in Fmr1-/y mice. (a) 
Representative traces of mEPSCs from pyramidal cells in hippocampal slice cultures from WT 
and Fmr1-/y mice treated with vehicle or 50 μM metformin for 4-5 days prior to recording. (b) 
Bar graphs showing that metformin treatment corrected the increase in mEPSC frequency in 
vehicle-treated Fmr1-/y neurons (2.71 ± 0.87 Hz) as compared to WT neurons (0.62 ± 0.16 Hz), 
with no effect on mEPSC amplitude. **P < 0.01; N.S., not significant; two-way repeated 
measures ANOVA with Tukey’s post hoc test; n = 10 recordings per group. All values are 
shown as mean ± s.e.m.  
 
 
 
Supplementary Figure 8 Chronic metformin treatment failed to reduce phosphorylation of S6 
(S240/244), AMPK, ACC1, TSC2 and Raptor in Fmr1-/y mice. Representative immunoblots 
and blot quantification of prefrontal cortex (a) and hippocampal (b) lysates from vehicle- and 
metformin-treated WT and Fmr1-/y mice probed for total and phosphorylated S6 (S240/244) (n 
= 6 in each group). Representative immunoblots of prefrontal cortex (c) and hippocampal (f) 
lysates from vehicle- and metformin-treated WT and Fmr1-/y mice probed for total and 
phosphorylated AMPK, and ACC1, and quantification of total and phosphorylated levels of (d) 
AMPK and (e) ACC1 in the prefrontal cortex, and (g) AMPK, and (h) ACC1 in the 
hippocampus (n = 6 in each group). (i) Representative immunoblots of hippocampal lysates 
from vehicle- and metformin-treated WT and Fmr1-/y mice probed for total and phosphorylated 
TSC2 and Raptor, and quantification of total and phosphorylated levels of (j) TSC2 and (k) 
Raptor (n = 4 in each group). GAPDH was used as a loading control. For quantification, the 
phospho-protein signal was normalized first against total protein, and then presented relative to 
vehicle-treated WT. Values are shown as mean ± s.e.m. **P < 0.01, *P < 0.05, N.S. not 
significant, versus all other groups; calculated by two-way repeated measures ANOVA with 
Tukey’s post hoc test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Supplementary Figure 9 Chronic metformin treatment reduced total B-Raf and C-Raf proteins 
in the hippocampus of Fmr1-/y mice. Representative immunoblots and blot quantification of 
total and phosphorylated B-Raf (a), and total C-Raf (b) from vehicle- and metformin-treated 
WT and Fmr1-/y mice (n = 6 in each group). GAPDH was used as a loading control. For 
quantification, the phospho-protein signal was normalized first against total protein, and then 
presented relative to vehicle-treated WT. Values are shown as mean ± s.e.m. ***P < 0.001, **P 
< 0.01, N.S. not significant, versus all other groups; calculated by two-way repeated measures 
ANOVA with Tukey’s post hoc test. (c) Proposed action of chronic metformin treatment to 
reduce hyperactivated ERK signaling in the brain of Fmr1-/y mouse.  
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Figure 10 Chronic metformin treatment reduced phosphorylated ERK in the 
striatum, but not in cerebellum, gonads and liver of Fmr1-/y mice. Representative immunoblots 
and blot quantification of total and phosphorylated ERK in the striatum (a), cerebellum (b), 
gonads (c), and liver (d) from vehicle- and metformin-treated WT and Fmr1-/y mice (n = 4 in 
each group). GAPDH was used as a loading control. For quantification, the phospho-protein 
signal was normalized first against total protein, and then presented relative to vehicle-treated 
WT. Values are shown as mean ± s.e.m. *P < 0.05, N.S. not significant, versus all other groups; 
calculated by two-way repeated measures ANOVA with Tukey’s post hoc test. 
 
  
 Supplementary Figure 11 Chronic metformin treatment reduced levels of FMRP targets, 
synapsin and MAP2 a,b in the hippocampus of Fmr1-/y mice. Representative immunoblots (a) 
and blot quantification of synapsin (b), eEF2 (c), PUM2 (d) and MAP2 a,b (e) in the 
hippocampus from vehicle- and metformin-treated WT and Fmr1-/y mice (n = 4 in each group). 
GAPDH was used as a loading control. For quantification, the protein signal was normalized 
first against loading control, and then presented relative to vehicle-treated WT. Values are 
shown as mean ± s.e.m. **P < 0.01, *P < 0.05, N.S. not significant, versus all other groups; 
calculated by two-way repeated measures ANOVA with Tukey’s post hoc test. 
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Supplementary Figure 12 Original images of representative western blots of de novo protein 
synthesis 
 
 
 
 
 
15 
 
 
Supplementary Figure 13 Original images of representative western blots in Fig. 2 
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Supplementary Figure 14 Original images of representative western blots in Fig. 2, and 
Supplementary Figs. 1 and 3 
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Supplementary Figure 15 Original images of representative western blots in Supplementary 
Fig. 8 
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Supplementary Figure 16 Original images of representative western blots in Supplementary 
Figs. 9 and 10 
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Supplementary Figure 17 Original images of representative western blots in Supplementary 
Fig. 11 
 
 
Supplementary Table 1. Statistical analysis for Figures 1-2 and Supplementary Figures 1-11.
*Supplementary Figures data (mean ± s.e.m.) is available upon request.
1b, c: Preference for social novelty Two-way mixed ANOVA
Time sniffing Post hoc  Tukey’s test: S1:
WT Veh (n = 10) Chamber: F(1,37) = 48.173, p < 0.001 WT Veh vs KO Veh, p = 0.006 WT Veh 35 ± 4
Fmr1-/y Veh (n = 10) Group: F(3,37) = 2.329, p = 0.090 WT Met vs KO Met, p = 0.971 KO Veh 73 ± 13
WT Met (n = 9) Chamber x Group: F(3,37) = 4.392, p = 0.010 WT Veh vs WT Met, p = 0.963 WT Met 40 ± 5
Fmr1-/y Met (n = 12) KO Veh vs KO Met, p = 0.005 KO Met 36 ± 6
S2:
WT Veh 79 ± 6
KO Veh 77 ± 11
WT Met 85 ± 10
KO Met 68 ± 7
Time in chamber Post hoc  Tukey’s test: S1:
Chamber: F(1,37) = 25.241, p < 0.001 WT Veh vs KO Veh, p = 0.013 WT Veh 153 ± 10
Group: F(3,37) = 3.600, p = 0.022 WT Met vs KO Met, p = 0.968 KO Veh 204 ± 14
Chamber x Group: F(3,37) = 0.456, p = 0.715 WT Veh vs WT Met, p = 0.997 WT Met 171 ± 10
KO Veh vs KO Met, p = 0.017 KO Met 159 ± 9
Centre:
WT Veh 235 ± 19
KO Veh 159 ± 18
WT Met 212 ± 17
KO Met 219 ± 15
S2:
WT Veh 212 ± 16
KO Veh 237 ± 15
WT Met 217 ± 11
KO Met 222 ± 15
1d, e: Grooming Two-way ANOVA
WT Veh (n = 10) Time Post hoc  Tukey’s test:
Fmr1-/y Veh (n = 10) Genotype: F(1,36) = 10.662, p = 0.002 WT Veh vs KO Veh, p < 0.001 WT Veh 18.1 ± 3.0
WT Met (n = 8) Treatment: F(1,36) = 4.613, p = 0.039 WT Met vs KO Met, p = 0.455 KO Veh 38.5 ± 2.5
Fmr1-/y Met (n = 12) Genotype x Treatment: F(1,36) = 4.782, p = 0.035 WT Veh vs WT Met, p = 0.979 WT Met 18.2 ± 4.8
KO Veh vs KO Met, p = 0.003 KO Met 22.3 ± 4.1
Number of bouts Post hoc  Tukey’s test:
Genotype: F(1,36) = 11.672, p = 0.002 WT Veh vs KO Veh, p < 0.001 WT Veh 6.2 ± 0.6
Treatment: F(1,36) = 4.767, p = 0.036 WT Met vs KO Met, p = 0.977 KO Veh 12.9 ± 1.2
Genotype x Treatment: F(1,36) = 11.386, p = 0.002 WT Veh vs WT Met, p = 0.428 WT Met 7.4 ± 1.3
Figure and nr of animals or cells 
used
Statistical analysis Post hoc tests Mean ± s.e.m.
KO Veh vs KO Met, p < 0.001 KO Met 7.3 ± 0.9
1g, h: Spine density Two-way ANOVA
WT Veh (n = 4) Nr of spines Post hoc  Tukey’s test:
Fmr1-/y Veh (n = 4) Genotype: F(1,32) = 26.741, p < 0.001 WT Veh vs KO Veh, p < 0.001 WT Veh 15.3 ± 0.5
WT Met (n = 4) Treatment: F(1,32) = 6.000, p = 0.02 WT Met vs KO Met, p = 0.447 KO Veh 21.0 ± 0.8
Fmr1-/y Met (n = 4) Genotype x Treatment: F(1,32) = 16.667, p < 0.001 WT Veh vs WT Met, p = 0.257 WT Met 16.3 ± 0.6
KO Veh vs KO Met, p < 0.001 KO Met 17.0 ± 0.6
Mushroom Post hoc  Tukey’s test:
Genotype: F(1,32) = 108.587, p < 0.001 WT Veh vs KO Veh, p < 0.001 WT Veh 31.4 ± 0.8
Treatment: F(1,32) = 49.390, p < 0.001 WT Met vs KO Met, p = 0.262 KO Veh 18.2 ± 0.8
Genotype x Treatment: F(1,32) = 77.527, p < 0.001 WT Veh vs WT Met, p = 0.218 WT Met 30.2 ± 0.7
KO Veh vs KO Met, p < 0.001 KO Met 29.1 ± 0.3
Filopodial Post hoc  Tukey’s test:
Genotype: F(1,32) = 71.558, p < 0.001 WT Veh vs KO Veh, p < 0.001 WT Veh 5.1 ± 0.3
Treatment: F(1,32) = 23.558, p < 0.001 WT Met vs KO Met, p = 0.016 KO Veh 10.4 ± 0.4
Genotype x Treatment: F(1,32) = 23.558, p < 0.001 WT Veh vs WT Met, p = 1.000 WT Met 5.1 ± 0.3
KO Veh vs KO Met, p < 0.001 KO Met 6.6 ± 0.6
1k: LTD Two-way ANOVA
Post hoc  Tukey’s test:
WT Veh (n = 9) Genotype: F(1,46) = 1.075, p = 0.305 WT Veh vs KO Veh, p = 0.032 WT Veh 75 ± 9
Fmr1-/y Veh (n = 17) Treatment: F(1,46) = 0.457, p = 0.503 WT Met vs KO Met, p = 0.480 KO Veh 55 ± 5
WT Met (n = 9) Genotype x Treatment: F(1,46) = 4.222, p < 0.046 WT Veh vs WT Met, p = 0.393 WT Met 66 ± 8
Fmr1-/y Met (n = 15) KO Veh vs KO Met, p = 0.028 KO Met 72 ± 5
2a: Testicle weight Two-way ANOVA
Post hoc  Tukey’s test:
WT Veh (n = 6) Genotype: F(1,21) = 32.605, p < 0.001 WT Veh vs KO Veh, p < 0.001 WT Veh 149 ± 6
Fmr1-/y Veh (n = 6) Treatment: F(1,21) = 8.846, p = 0.007 WT Met vs KO Met, p = 0.004 KO Veh 200 ± 5
WT Met (n = 6) Genotype x Treatment: F(1,21) = 1.596, p = 0.220 WT Veh vs WT Met, p = 0.248 WT Met 137 ± 6
Fmr1-/y Met (n = 7) KO Veh vs KO Met, p = 0.006 KO Met 170 ± 8
2b: De novo  protein synthesis Two-way ANOVA
Post hoc  Tukey’s test:
WT Veh (n = 7) Genotype: F(1,24) = 2.454, p = 0.130 WT Veh vs KO Veh, p = 0.021 WT Veh 1.00 ± 0.01
Fmr1-/y Veh (n = 7) Treatment: F(1,24) = 6.198, p = 0.02 WT Met vs KO Met, p = 0.792 KO Veh 1.29 ± 0.09
WT Met (n = 7) Genotype x Treatment: F(1,24) = 3.782, p = 0.064 WT Veh vs WT Met, p = 0.704 WT Met 0.95 ± 0.04
Fmr1-/y Met (n = 7) KO Veh vs KO Met, p = 0.005 KO Met 0.92 ± 0.12
2c-j: Western blot Two-way ANOVA
For all data except for MMP-9 in 
prefrontal cortex:
Prefrontal cortex Post hoc  Tukey’s test:
p-MEK/MEK WT Veh vs KO Veh, p = 0.027 WT Veh 100 ± 14
WT Veh (n = 6) Genotype: F(1,20) = 8.693, p = 0.008 WT Met vs KO Met, p = 0.705 KO Veh 162 ± 17
Fmr1-/y Veh (n = 6) Treatment: F(1,20) = 5.660, p = 0.027 WT Veh vs WT Met, p = 0.904 WT Met 86 ± 10
WT Met (n = 6) Genotype x Treatment: F(1,20) = 2.016, p = 0.171 KO Veh vs KO Met, p = 0.014 KO Met 108 ± 15
Fmr1-/y Met (n = 6)
MEK/GAPDH WT Veh 100 ± 6
Genotype: F(1,20) = 0.021, p = 0.887 KO Veh 98 ± 6
Treatment: F(1,20) = 0.250, p = 0.623 WT Met 102 ± 4
Genotype x Treatment: F(1,20) = 0.017, p = 0.896 KO Met 102 ± 9
p-ERK/ERK Post hoc  Tukey’s test:
Genotype: F(1,20) = 15.141, p < 0.001 WT Veh vs KO Veh, p < 0.001 WT Veh 100 ± 22
Treatment: F(1,20) = 7.636, p = 0.012 WT Met vs KO Met, p = 0.905 KO Veh 201 ± 12
Genotype x Treatment: F(1,20) = 8.609, p = 0.008 WT Veh vs WT Met, p = 0.999 WT Met 103 ± 12
KO Veh vs KO Met, p = 0.003 KO Met 117 ± 10
ERK/GAPDH WT Veh 100 ± 6
Genotype: F(1,20) = 0.000, p = 0.997 KO Veh 103 ± 5
Treatment: F(1,20) = 0.956, p = 0.340 WT Met 98 ± 7
Genotype x Treatment: F(1,20) = 0.320, p = 0.578 KO Met 94 ± 6
p-eIF4E/eIF4E Post hoc  Tukey’s test:
Genotype: F(1,20) = 1.404, p = 0.250 WT Veh vs KO Veh, p = 0.023 WT Veh 100 ± 5
Treatment: F(1,20) = 5.023, p = 0.036 WT Met vs KO Met, p = 0.458 KO Veh 129 ± 7
Genotype x Treatment: F(1,20) = 10.899, p = 0.003 WT Veh vs WT Met, p = 0.877 WT Met 107 ± 5
KO Veh vs KO Met, p = 0.004 KO Met 93 ± 8
eIF4E/GAPDH WT Veh 100 ± 15
Genotype: F(1,20) = 3.583, p = 0.073 KO Veh 147 ± 10
Treatment: F(1,20) = 4.255, p = 0.052 WT Met 149 ± 7
Genotype x Treatment: F(1,20) = 3.050, p = 0.096 KO Met 151 ± 17
WT Veh (n = 5) MMP-9/GAPDH Post hoc  Tukey’s test:
Fmr1-/y Veh (n = 5) Genotype: F(1,16) = 2.891, p = 0.108 WT Veh vs KO Veh, p = 0.023 WT Veh 100 ± 14
WT Met (n = 5) Treatment: F(1,16) = 6.638, p =0.020 WT Met vs KO Met, p = 0.830 KO Veh 146 ± 8
Fmr1-/y Met (n = 5) Genotype x Treatment: F(1,20) = 8.415, p = 0.010 WT Veh vs WT Met, p = 0.996 WT Met 103 ± 4
KO Veh vs KO Met, p = 0.007 KO Met 91 ± 12
Hippocampus Post hoc  Tukey’s test:
p-MEK/MEK WT Veh vs KO Veh, p < 0.001 WT Veh 100 ± 5
Genotype: F(1,20) = 6.175, p = 0.022 WT Met vs KO Met, p = 0.667 KO Veh 174 ± 11
Treatment: F(1,20) = 15.178, p < 0.001 WT Veh vs WT Met, p = 0.999 WT Met 102 ± 16
Genotype x Treatment: F(1,20) = 16.846, p < 0.001 KO Veh vs KO Met, p < 0.001 KO Met 84 ± 11
MEK/GAPDH WT Veh 100 ± 8
Genotype: F(1,20) = 0.265, p = 0.612 KO Veh 118 ± 7
Treatment: F(1,20) = 1.298, p = 0.268 WT Met 105 ± 7
Genotype x Treatment: F(1,20) = 3.077, p = 0.095 KO Met 95 ± 10
p-ERK/ERK Post hoc  Tukey’s test:
Genotype: F(1,20) = 2.749, p = 0.113 WT Veh vs KO Veh, p = 0.019 WT Veh 100 ± 5
Treatment: F(1,20) = 5.618, p = 0.028 WT Met vs KO Met, p = 0.797 KO Veh 140 ± 8
Genotype x Treatment: F(1,20) = 8.715, p = 0.008 WT Veh vs WT Met, p = 0.976 WT Met 105 ± 7
KO Veh vs KO Met, p = 0.006 KO Met 94 ± 13
ERK/GAPDH WT Veh 100 ± 2
Genotype: F(1,20) = 0.109, p = 0.744 KO Veh 101 ± 5
Treatment: F(1,20) = 0.350, p = 0.561 WT Met 97 ± 6
Genotype x Treatment: F(1,20) = 0.004, p = 0.950 KO Met 99 ± 5
p-eIF4E/eIF4E Post hoc  Tukey’s test:
Genotype: F(1,20) = 16.194, p < 0.001 WT Veh vs KO Veh, p = 0.002 WT Veh 100 ± 5
Treatment: F(1,20) = 18.973, p < 0.001 WT Met vs KO Met, p = 0.494 KO Veh 166 ± 16
Genotype x Treatment: F(1,20) = 3.989, p = 0.059 WT Veh vs WT Met, p = 0.366 WT Met 122 ± 9
KO Veh vs KO Met, p = 0.001 KO Met 149 ± 12
eIF4E/GAPDH
Genotype: F(1,20) = 0.739, p = 0.400 WT Veh 100 ± 22
Treatment: F(1,20) = 0.769, p = 0.391 KO Veh 128 ± 24
Genotype x Treatment: F(1,20) = 3.866, p = 0.063 WT Met 105 ± 16
KO Met 122 ± 20
MMP-9/GAPDH Post hoc  Tukey’s test:
Genotype: F(1,20) = 16.803, p < 0.001 WT Veh vs KO Veh, p < 0.001 WT Veh 100 ± 6
Treatment: F(1,20) = 11.770, p = 0.003 WT Met vs KO Met, p = 0.978 KO Veh 159 ± 8
Genotype x Treatment: F(1,20) = 12.526, p = 0.002 WT Veh vs WT Met, p = 0.999 WT Met 101 ± 10
KO Veh vs KO Met, p < 0.001 KO Met 105 ± 8
Supplementary 1a, b: One-way ANOVA
Pharmacokinetics Plasma Post hoc  Tukey’s test:
Time: F(4,15) = 6.964, p = 0.002 0 vs 0.5, p = 0.005
0.5 vs 1, p = 0.241
0 h (n = 4) 0.5 vs 2, p = 0.008
0.5 h (n = 4) 0.5 vs 4, p = 0.006
1 h (n = 4)
2 h (n = 4) Brain Post hoc  Tukey’s test:
4 h (n = 4) Time: F(4,15) = 5.936, p = 0.005 0 vs 0.5, p = 0.006
0.5 vs 1, p = 0.998
0.5 vs 2, p = 0.463
0.5 vs 4, p = 0.131
Supplementary 1c: One-way ANOVA Post hoc  Tukey’s test:
Western blot Hippocampus 0 vs 0.5, p = 0.998
p-AMPK/AMPK 0  vs 1, p = 0.089
0 h  (n = 3) Time: F(4,10) = 5.072, p = 0.017 0 vs 2, p = 0.033
0.5 h (n = 3) 0 vs 4, p = 0.845
1 h (n = 3)
*
2 h (n = 3)
4 h (n = 3)
Supplementary 2a, b: One-way ANOVA Post hoc  Tukey’s test:
Dose-response Plasma 25 vs 50, p = 0.996
Time: F(3,12) = 7.017, p = 0.006 25 vs 100, p = 0.078
25 mg/kg  (n = 4) 25 vs 200, p = 0.012
50 mg/kg  (n = 4)
100 mg/kg  (n = 4) Brain Post hoc  Tukey’s test:
200 mg/kg   (n = 4) Time: F(3,12) = 98.789, p < 0.001 25 vs 50, p = 0.091
25 vs 100, p < 0.001
25 vs 200, p < 0.001
Supplementary 3a: Two-way mixed ANOVA
Preference for social novelty Time sniffing Post hoc  Tukey’s test:
Chamber: F(1,28) = 30.489, p < 0.001 WT Veh vs KO Veh, p = 0.046
WT Veh (n = 8) Group: F(3,28) = 5.016, p = 0.007 WT Met vs KO Met, p = 0.011
Fmr1-/y Veh (n = 8) Chamber x Group: F(3,28) = 10.210, p < 0.001 WT Veh vs WT Met, p = 0.928
WT Met (n = 8) KO Veh vs KO Met, p = 0.821
Fmr1-/y Met (n = 8)
Time in chamber Post hoc  Tukey’s test:
Chamber: F(1,28) = 8.850, p = 0.006 WT Veh vs KO Veh, p = 0.646
Group: F(3,28) = 1.735, p = 0.183 WT Met vs KO Met, p = 0.252
Chamber x Group: F(3,28) = 0.964, p = 0.424 WT Veh vs WT Met, p = 0.372
KO Veh vs KO Met, p = 0.694 
Supplementary 3b Two-way ANOVA
5-day metformin grooming Time grooming
Genotype: F(1,20) = 14.904, p < 0.001 Post hoc  Tukey’s test:
WT Veh (n = 6) Treatment: F(1,20) = 0.004, p = 0.947 WT Veh vs KO Veh, p = 0.005
Fmr1-/y Veh (n = 6) Genotype x Treatment: F(1,20) = 1.020, p = 0.325 WT Met vs KO Met, p = 0.037
WT Met (n = 7) WT Veh vs WT Met, p = 0.536
Fmr1-/y Met (n = 7) KO Veh vs KO Met, p = 0.427
Supplementary 3c Two-way ANOVA
 5-day metformin LTD Post hoc  Tukey’s test:
Genotype: F(1,45) = 1.642, p = 0.207 WT Veh vs KO Veh, p = 0.022
WT Veh (n = 13) Treatment: F(1,45) = 3.643, p = 0.063 WT Met vs KO Met, p = 0.590
Fmr1-/y Veh (n = 12) Genotype x Treatment: F(1,45) = 4.232, p = 0.045 WT Veh vs WT Met, p = 0.916
WT Met (n = 12) KO Veh vs KO Met, p = 0.008
Fmr1-/y Met (n = 12)
Supplementary 3d Two-way ANOVA
5-day metformin De novo  protein 
synthesis
Post hoc  Tukey’s test:
Genotype: F(1,8) = 48.306, p < 0.001 WT Veh vs KO Veh, p = 0.006
WT Veh (n = 3) Treatment: F(1,8) = 0.048, p = 0.832 WT Met vs KO Met, p = 0.005
Fmr1-/y Veh (n = 3) Genotype x Treatment: F(1,8) = 0.023, p = 0.883 WT Veh vs WT Met, p = 1.000
WT Met (n = 3) KO Veh vs KO Met, p = 0.993
Fmr1-/y Met (n = 3)
Supplementary 3e Two-way ANOVA
5-day metformin Western blot Prefrontal cortex Post hoc  Tukey’s test:
p-eIF4E/eIF4E WT Veh vs KO Veh, p = 0.001
WT Veh (n = 6) Genotype: F(1,20) = 27.037, p < 0.001 WT Met vs KO Met, p = 0.045
Fmr1-/y Veh (n = 6) Treatment: F(1,20) = 4.028, p = 0.058 WT Veh vs WT Met, p = 0.934
WT Met (n = 6) Genotype x Treatment: F(1,20) = 1.376, p = 0.254 KO Veh vs KO Met, p = 0.144
Fmr1-/y Met (n = 6)
Hippocampus Post hoc  Tukey’s test:
p-eIF4E/eIF4E WT Veh vs KO Veh, p = 0.037
Genotype: F(1,20) = 7.664, p = 0.012 WT Met vs KO Met, p = 0.766
Treatment: F(1,20) = 1.243, p = 0.278 WT Veh vs WT Met, p = 0.997
Genotype x Treatment: F(1,20) = 1.936, p = 0.179 KO Veh vs KO Met, p = 0.315
Supplementary 4a Two-way ANOVA
1-day metformin grooming Time grooming Post hoc  Tukey’s test:
Genotype: F(1,20) = 12.461, p = 0.002 WT Veh vs KO Veh, p = 0.019
WT Veh (n = 6) Treatment: F(1,20) = 1.279, p = 0.271 WT Met vs KO Met, p = 0.025
Fmr1-/y Veh (n = 6) Genotype x Treatment: F(1,20) = 0.009, p = 0.924 WT Veh vs WT Met, p = 0.473
WT Met (n = 6) KO Veh vs KO Met, p = 0.396
Fmr1-/y Met (n = 6)
Supplementary 4b Two-way ANOVA
1-day metformin LTD Post hoc  Tukey’s test:
Genotype: F(1,37) = 5.636, p = 0.023 WT Veh vs KO Veh, p = 0.009
WT Veh (n = 11) Treatment: F(1,37) = 0.196, p = 0.661 WT Met vs KO Met, p = 0.512
Fmr1-/y Veh (n = 10) Genotype x Treatment: F(1,37) = 2.008, p = 0.165 WT Veh vs WT Met, p = 0.465
WT Met (n = 12) KO Veh vs KO Met, p = 0.223
Fmr1-/y Met (n = 8)
Supplementary 4c Two-way ANOVA
1-day metformin De novo  protein 
synthesis
Genotype: F(1,8) = 37.400, p < 0.001 Post hoc  Tukey’s test:
WT Veh (n = 3) Treatment: F(1,8) = 0.075, p = 0.791 WT Veh vs KO Veh, p = 0.009
Fmr1-/y Veh (n = 3) Genotype x Treatment: F(1,8) = 0.014, p = 0.909 WT Met vs KO Met, p = 0.012
WT Met (n = 3) WT Veh vs WT Met, p = 0.992
Fmr1-/y Met (n = 3) KO Veh vs KO Met, p = 0.999
Supplementary 5b Two-way ANOVA
Open Field Path length Post hoc  Tukey’s test:
Genotype: F(1,26) = 22.131, p < 0.001 WT Veh vs KO Veh, p = 0.001
WT Veh (n = 8) Treatment: F(1,26) = 0.053, p = 0.819 WT Met vs KO Met, p = 0.006
Fmr1-/y Veh (n = 7) Genotype x Treatment: F(1,26) = 0.213, p = 0.648 WT Veh vs WT Met, p = 0.867
WT Met (n = 8) KO Veh vs KO Met, p = 0.640
Fmr1-/y Met (n = 8)
Velocity Post hoc  Tukey’s test:
Genotype: F(1,26) = 21.530, p < 0.001 WT Veh vs KO Veh, p = 0.002
Treatment: F(1,26) = 0.025, p = 0.875 WT Met vs KO Met, p = 0.006
Genotype x Treatment: F(1,26) = 0.118, p = 0.733 WT Veh vs WT Met, p = 0.893
KO Veh vs KO Met, p = 0.733
Supplementary 5c Two-way ANOVA
Light-dark box Post hoc  Tukey’s test:
Genotype: F(1,28) = 14.337, p < 0.001 WT Veh vs KO Veh, p = 0.038
WT Veh (n = 8) Treatment: F(1,28) = 0.713, p = 0.406 WT Met vs KO Met, p = 0.004
Fmr1-/y Veh (n = 8) Genotype x Treatment: F(1,28) = 0.489, p = 0.490 WT Veh vs WT Met, p = 0.285
WT Met (n = 8) KO Veh vs KO Met, p = 0.919
Fmr1-/y Met (n = 8)
Supplementary 6a-d Two-way mixed ANOVA
Morris Water Maze Acquisition MWM
Group: F(3,112) = 0.892, p = 0.458  
WT Veh (n = 8) Day: F(4,112) = 111.265, p < 0.001
Fmr1-/y Veh (n = 8) Group x Day: F(12,112) = 0.495, p = 0.914
WT Met (n = 8)
Fmr1-/y Met (n = 8)
Two-way ANOVA
Probe MWM
Genotype: F(1,28) = 0.417, p = 0.524
Treatment: F(1,28) = 1.094, p = 0.305
Genotype x Treatment: F(1,28) = 0.009, p = 0.923
Two-way mixed ANOVA
Acquisition reversal MWM
Group: F(3,140) = 1.973, p = 0.141
Trial: F(5,140) = 10.687, p < 0.001
Group x Trial: F(15,140) = 0.586, p = 0.882
Two-way ANOVA
Probe reversal MWM
Genotype: F(1,28) = 0.173, p = 0.681
Treatment: F(1,28) = 0.183, p = 0.672
Genotype x Treatment: F(1,28) = 0.554, p = 0.463
Supplementary 6e Two-way ANOVA
CFC
Genotype: F(1,26) = 1.127, p = 0.298  
WT Veh (n = 8) Treatment: F(1,26) = 1.001, p = 0.326
Fmr1-/y Veh (n = 8) Genotype x Treatment: F(1,26) = 0.006, p = 0.937
WT Met (n = 8)
Fmr1-/y Met (n = 10)
Supplementary 6f Two-way ANOVA
NOR  
Genotype: F(1,28) = 0.488, p = 0.491
WT Veh (n = 8) Treatment: F(1,28) = 0.669, p = 0.402
Fmr1-/y Veh (n = 8) Genotype x Treatment: F(1,28) = 0.488, p = 0.491
WT Met (n = 8)
Fmr1-/y Met (n = 8)
Supplementary 7b Two-way ANOVA
mEPSC
Frequency Post hoc  Tukey’s test:
WT Veh (n = 10) Genotype: F(1,36) = 3.247, p = 0.080 WT Veh vs KO Veh, p = 0.003
Fmr1-/y Veh (n = 10) Treatment: F(1,36) = 2.952, p = 0.094 WT Met vs KO Met, p = 0.537
WT Met (n = 10) Genotype x Treatment: F(1,36) = 7.204, p = 0.011 WT Veh vs WT Met, p = 0.499
Fmr1-/y Met (n = 10) KO Veh vs KO Met, p = 0.004
Amplitude Post hoc  Tukey’s test:
Genotype: F(1,36) = 6.766, p = 0.013 WT Veh vs KO Veh, p = 0.134
Treatment: F(1,36) = 0.864, p = 0.359 WT Met vs KO Met, p = 0.039
Genotype x Treatment: F(1,36) = 0.185, p = 0.670 WT Veh vs WT Met, p = 0.343
KO Veh vs KO Met, p = 0.726
Supplementary 8a-k: Two-way ANOVA
Western blot Prefrontal cortex Post hoc  Tukey’s test:
p-S6/S6 WT Veh vs KO Veh, p = 0.505
For all data except for p-TSC2 and p-
Raptor  in hippocampus:
Genotype: F(1,20) = 2.594, p = 0.123 WT Met vs KO Met, p = 0.824
WT Veh (n = 6) Treatment: F(1,20) = 7.681, p = 0.012 WT Veh vs WT Met, p = 0.358
Fmr1-/y Veh (n = 6) Genotype x Treatment: F(1,20) = 0.152, p = 0.701 KO Veh vs KO Met, p = 0.148
WT Met (n = 6)
Fmr1-/y Met (n = 6)
p-AMPK/AMPK
Genotype: F(1,20) = 0.999, p = 0.329
Treatment: F(1,20) = 1.353, p = 0.258
Genotype x Treatment: F(1,20) = 0.060, p = 0.809
p-ACC1/ACC1
Genotype: F(1,20) = 4.121, p = 0.056
Treatment: F(1,20) = 2.326, p = 0.143
Genotype x Treatment: F(1,20) = 1.851, p = 0.189
Hippocampus Post hoc  Tukey’s test:
p-S6/S6 WT Veh vs KO Veh, p = 0.047
Genotype: F(1,20) = 16.293, p < 0.001 WT Met vs KO Met, p = 0.043
Treatment: F(1,20) = 1.782, p = 0.197 WT Veh vs WT Met, p = 0.770
Genotype x Treatment: F(1,20) = 0.001, p = 0.975 KO Veh vs KO Met, p = 0.794
Post hoc  Tukey’s test:
S6/GAPDH WT Veh vs KO Veh, p = 0.006
Genotype: F(1,20) = 7.909, p = 0.011 WT Met vs KO Met, p = 0.995
Treatment: F(1,20) = 0.584, p = 0.454 WT Veh vs WT Met, p = 0.133
Genotype x Treatment: F(1,20) = 6.149, p = 0.022 KO Veh vs KO Met, p = 0.626
p-AMPK/AMPK
Genotype: F(1,20) = 0.305, p = 0.587
Treatment: F(1,20) = 0.013, p = 0.910
Genotype x Treatment: F(1,20) = 0.034, p = 0.856
Post hoc  Tukey’s test:
p-ACC1/ACC1 WT Veh vs KO Veh, p = 0.180
Genotype: F(1,20) = 5.626, p = 0.028 WT Met vs KO Met, p = 0.615
Treatment: F(1,20) = 0.835, p = 0.371 WT Veh vs WT Met, p = 0.698
Genotype x Treatment: F(1,20) = 0.397, p = 0.536 KO Veh vs KO Met, p = 0.997
WT Veh (n = 4)
Fmr1-/y Veh (n = 4) p-TSC2/TSC2
WT Met (n = 4) Genotype: F(1,12) = 0.184, p = 0.676
Fmr1-/y Met (n = 4) Treatment: F(1,12) = 0.005, p = 0.947
Genotype x Treatment: F(1,12) = 0.915, p = 0.358
WT Veh (n = 4)
Fmr1-/y Veh (n = 4) p-Raptor/Raptor
WT Met (n = 4) Genotype: F(1,12) = 0.076, p = 0.788
Fmr1-/y Met (n = 4) Treatment: F(1,12) = 0.384, p = 0.547
Genotype x Treatment: F(1,12) = 0.000, p = 0.983
Supplementary 9a, b: Two-way ANOVA
Western blot Hippocampus Post hoc  Tukey’s test:
b-Raf/GAPDH WT Veh vs KO Veh, p = 0.004
WT Veh (n = 6) Genotype: F(1,20) = 0.044, p = 0.836 WT Met vs KO Met, p = 0.007
Fmr1-/y Veh (n = 6) Treatment: F(1,20) = 4.555, p = 0.045 WT Veh vs WT Met, p = 0.124
WT Met (n = 6) Genotype x Treatment: F(1,20) = 29.514, p < 0.001 KO Veh vs KO Met, p < 0.001
Fmr1-/y Met (n = 6)
p-b-Raf S729/ b-Raf
Genotype: F(1,20) = 3.925, p = 0.061
Treatment: F(1,20) = 4.900, p = 0.039
Genotype x Treatment: F(1,20) = 0.539, p = 0.471
p-b-Raf S602/ b-Raf
Genotype: F(1,20) = 0.253, p = 0.620
Treatment: F(1,20) = 1.872, p = 0.186
Genotype x Treatment: F(1,20) = 0.195, p = 0.663
c-Raf/GAPDH Post hoc  Tukey’s test:
Genotype: F(1,20) = 2.498, p = 0.130 WT Veh vs KO Veh, p = 0.003
Treatment: F(1,20) = 2.616, p = 0.121 WT Met vs KO Met, p = 0.267
Genotype x Treatment: F(1,20) = 17.981, p < 0.001 WT Veh vs WT Met, p = 0.278
KO Veh vs KO Met, p = 0.003
Supplementary 10a-d: Two-way ANOVA
Western blot Striatum Post hoc  Tukey’s test:
p-ERK/ERK WT Veh vs KO Veh, p = 0.019
Genotype: F(1,12) = 6.057, p = 0.030 WT Met vs KO Met, p = 1.000
Treatment: F(1,12) = 3.793, p = 0.075 WT Veh vs WT Met, p = 0.977
WT Veh (n = 4) Genotype x Treatment: F(1,12) = 6.325, p = 0.027 KO Veh vs KO Met, p = 0.036
Fmr1-/y Veh (n = 4)
WT Met (n = 4)
Fmr1-/y Met (n = 4) Cerebellum Post hoc  Tukey’s test:
p-ERK/ERK WT Veh vs KO Veh, p = 0.044
Genotype: F(1,12) = 11.142, p = 0.006 WT Met vs KO Met, p = 0.374
Treatment: F(1,12) = 0.644, p = 0.438 WT Veh vs WT Met, p = 0.999
Genotype x Treatment: F(1,12) = 0.923, p = 0.356 KO Veh vs KO Met, p = 0.611
Gonads
p-ERK/ERK
Genotype: F(1,12) = 0.093, p = 0.765
Treatment: F(1,12) = 5.606, p = 0.035
Genotype x Treatment: F(1,12) = 0.266, p = 0.625
Liver Post hoc  Tukey’s test:
p-ERK/ERK WT Veh vs KO Veh, p = 0.048
Genotype: F(1,12) = 11.427, p = 0.005 WT Met vs KO Met, p = 0.326
Treatment: F(1,12) = 0.245, p = 0.629 WT Veh vs WT Met, p = 0.994
Genotype x Treatment: F(1,12) = 0.729, p = 0.410 KO Veh vs KO Met, p = 0.777
Supplementary 11b-e Two-way ANOVA
Western blot Hippocampus Post hoc  Tukey’s test:
Synapsin/GAPDH WT Veh vs KO Veh, p = 0.014
WT Veh (n = 4) Genotype: F(1,12) = 5.891, p = 0.032 WT Met vs KO Met, p = 0.992
Fmr1-/y Veh (n = 4) Treatment: F(1,12) = 0.019, p = 0.891 WT Veh vs WT Met, p = 0.210
WT Met (n = 4) Genotype x Treatment: F(1,12) = 7.966, p = 0.015 KO Veh vs KO Met, p = 0.280
Fmr1-/y Met (n = 4)
eEF2/GAPDH  
Genotype: F(1,12) = 0.851, p = 0.374
Treatment: F(1,12) = 2.357, p = 0.151
Genotype x Treatment: F(1,12) = 2.183, p = 0.165
PUM2/GAPDH
Genotype: F(1,12) = 2.457, p = 0.143
Treatment: F(1,12) = 0.060, p = 0.810
Genotype x Treatment: F(1,12) = 0.907, p = 0.360
MAP2/GAPDH Post hoc  Tukey’s test:
Genotype: F(1,12) = 1.876, p = 0.196 WT Veh vs KO Veh, p = 0.083
Treatment: F(1,12) = 10.052, p = 0.008 WT Met vs KO Met, p = 0.882
Genotype x Treatment: F(1,12) = 5.782, p = 0.033 WT Veh vs WT Met, p = 0.947
KO Veh vs KO Met, p = 0.009
